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*rombotic thrombocytopenia purpura (TTP) is a hematological emergency that requires rapid assessment followed by prompt
initiation of therapy due to high mortality associated with delayed treatment. TTP has many causes including heritable syn-
dromes, ADAMTS13 deﬁciency, and drugs-related etiologies. Profound vitamin B12 deﬁciency can, in rare cases, mimic TTP in
presentation, and since plasmapheresis can be of limited beneﬁt, prompt diagnosis is necessary for accurate treatment with B12.
*erefore, careful analysis of all clinical signs, symptoms, and labs must be assessed. We report a patient who presented with a
diagnosis of TTP, and repeat assessment conﬁrmed a diagnosis of sever vitamin B12 (B12) deﬁciency with pancytopenia who was
appropriately treated with B12.
1. Introduction
TTP is characterized by a microangiopathic hemolytic
anemia (MAHA), thrombocytopenia, and end-organ dys-
function which requires accurate diagnosis and plasma-
pheresis [1]. With an incidence of 4 cases in 100000, TTP can
have multiple complications including rapid progression to
end-organ dysfunction and death [1, 2]. However, it is not
uncommon for other conditions, such as vitamin B12 de-
ﬁciency, to present in a similar fashion, with thrombocy-
topenia and microangiopathy. Hence, it is important to keep
in mind this rare syndrome in addition to other diﬀerential
diagnoses including disseminated intravascular coagulation
(DIC), hemolytic-uremic syndrome (HUS), and autoim-
mune hemolysis as they can often bemistaken for TTP [2, 3].
Because the results of ADAMTS13 are not readily available
at time of presentation, plasmapheresis is often initiated if
there is a suspicion for TTP. *e case below illustrates such
an example in which the patient presented with
pancytopenia and microangiopathy concerning for TTP.
Emergent plasmapheresis was initiated, and upon further
workup, the patient symptoms were attributable to a severe
vitamin B12 deﬁciency.
2. Case Presentation
A 70-year-old Caucasian woman with no past medical
history presented to her local care facility after sustaining a
mechanical fall the day prior to presentation. She endorsed
progressive fatigue, weakness, and dyspnea on exertion in
addition to symmetric, bilateral lower extremity numbness
for two months. Per her husband, she had become pro-
gressively more confused over the past week in addition to
endorsing new onset jaundice and scleral icterus.
On initial presentation, she was confused and dyspneic.
Lab work was signiﬁcant for a severe anemia with a he-
moglobin of 5.7 g/dL (12–16 g/dL). She received four units
of pRBCs and was subsequently transferred to our care
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facility for further evaluation. On presentation, tempera-
ture was 36.3°C, pulse 70 bpm, blood pressure 105/
57mmHg, respirations 18, and oxygen saturation of 100%
on room air. Physical exam ﬁndings were signiﬁcant for
mild scleral icterus and palpable splenomegaly. *e patient
was initially oriented to person only; however, the re-
mainder of the physical exam, including the neurological
exam, was unremarkable without motor or sensory deﬁcits
on initial presentation. Initial laboratory studies were
signiﬁcant for pancytopenia with WBC of 1.8 K/mm3
(4.0–11.0 K/mm3), hemoglobin of 8.3 g/dL (12–16 g/dL),
MCV of 103 fL (78–100 fL), RDW 24.7% (11.0–15.0%),
haptoglobin of <10mg/dL (43–212mg/dL), and platelets of
44 K/mm3 (130–450 K/mm3) (Table 1). Direct antiglobulin
test was negative. Her chemistry proﬁle was signiﬁcant for
a total bilirubin of 3.7mg/dL (0.2–1.3mg/dL) with a direct
bilirubin of 1.3mg/dL (0.1–0.5mg/dL), and a lactate de-
hydrogenase of 1908 IU/L. Liver chemistries and serum
creatinine were normal. Examination of a repeat peripheral
blood smear was signiﬁcant for hypersegmented neutro-
phils and moderate ovalocytes (Figure 1). In addition, there
was concern for schistocytes on the initial smear
prompting concern for TTP. At the time of presentation,
ADAMTS13 activity was pending. Initially, the patient
underwent plasmapheresis starting on admission, for a
total of three days in addition to prednisone. Repeat smear
was signiﬁcant for hypersegmented neutrophils and a
macrocytic normochromic anemia without evidence of an
increase in schistocytes or microspherocytes to suggest a
hemolytic process. Serum B12 level drawn on admission
was <150 pg/mL (200–650 pg/L). Serum folate level was
normal, and serum methylmalonic acid level was ordered
to conﬁrm the diagnosis of B12 deﬁciency and was sig-
niﬁcantly elevated at 36090 nmol/L (87–318 nmol/L). Anti-
intrinsic factor antibodies were positive. In addition, the
patient was found to be hypothyroid with TSH of
13.53mIU/L (0.4–4.0mIU/L) and free T4 of 0.58 ng/dL
and was started on synthroid at 100 μg daily. *e
ADAMTS13 result eventually returned within normal
limits. *erapy with intramuscular B12 was begun with
1000 μg daily, initiated on the same day as plasmapheresis,
for one week followed by 1000 μg weekly for four weeks and
then monthly thereafter for life. *e patient continued to
clinically improve with treatment. Repeat vitamin B12
levels one month after therapy were >2000 pg/mL. CBC
values also normalized after therapy (Table 2 and Figure 2).
Two months after initial therapy, the patient’s confusion
had resolved; however, her bilateral lower extremity
neuropathy continued to persist until the initiation of
gabapentin outpatient.
3. Discussion
TTP is an emergent diagnosis and necessitates rapid initiation
of plasmapheresis if there is suspicion on initial presentation.
Due to the high mortality associated with TTP, plasmaphe-
resis is still performed despite ADAMTS13 results not being
immediately available. *e list of differential diagnoses for
hemolytic anemia is broad and can include thrombotic
microangiopathies (TMA), autoimmune hemolytic anemia,
drug-induced hemolysis (cephalosporins, dapsone, and
levodopa), paroxysmal nocturnal hemoglobinuria (PNH),
and other hereditary syndromes [13]. Vitamin B12 deﬁciency
is not often associated with hemolytic anemia; however, upon
literature review, there have been multiple cases with similar
presentations [14] (Table 2). Vitamin B12 deﬁciency can cause
hemolytic anemia most commonly via intramedullary he-
molysis of immature reticulocytes; however, thrombotic
microangiopathy is rarely seen [15]. Reticulocytopenia in
cobalamin deﬁciency commonly reﬂects ineﬀective erythro-
poiesis in the setting of bone marrow involvement and
intramedullary destruction as opposed to peripheral hemo-
lysis as seen with TTP [15, 16]. *is mechanism is initiated by
premature death via hemolysis of the developing erythrocyte
precursors in the bone marrow and is associated with the
laboratory ﬁndings of hemolysis including elevated LDH,
bilirubin, and decreased haptoglobin [16, 17]. However, very
few cases of vitamin B12 deﬁciency have been linked with
MAHA, and previous studies indicate that this may arise from
acute hyperhomocystinemia which can lead to micro-
angiopathic hemolytic anemia termed pseudothrombotic
angiopathy [18]. *erefore, initial laboratory and pathologic
ﬁndings can often mimic TTP in severe cases of cobalamin
deﬁciency and in rare cases, such as ours, it can present with
microangiopathic hemolysis.
4. Conclusion
TTP is a life-threatening microangiopathic hemolytic ane-
mia that can lead to death without timely diagnosis and
Table 1: Lab values before and after therapy.
Lab values On presentation *ree weeks aftertherapy
Hemoglobin 5.7 g/dL 11.5 g/dL
MCV 103 fL 96 fL
Platelet count 44K/mm3 223K/mm3
White blood cell count 1.8 K/mm3 8.4 K/mm3
Haptoglobin <10mg/dL N/A
Total bilirubin/direct
bilirubin
3.7mg/dL/1.3mg/
dL 1.0mg/dL/NA
LDH 1908 IU/L 279 IU/L H
Serum B12 level <150 pg/mL >2000 pg/mL
Figure 1: Hypersegmented neutrophils and hypochromic eryth-
rocytes characteristic of a megaloblastic anemia. H&E stain.
Magniﬁcation: 400x.
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treatment with plasmapheresis. Due to the high mortality
associated with TTP, plasmapheresis should be initiated
despite pending ADAMTS13 results. As discussed above,
TTP can often mimic other common hemolytic anemias;
however, there are few cases where severe vitamin B12
deciency can result in a hemolytic anemia (Table 2). In
addition, pathologic ndings of severe B12 deciency can
often mimic hemolysis both biochemically and on initial
pathology [4, 18, 19]. In the presentation above, the initial
working diagnosis was TTP, and thus plasmapheresis was
initiated. After further workup and conrmation with
normal ADAMTS13 results, the patient was found to be
severely decient in vitamin B12. As discussed, studies have
shown that severe vitamin B12 deciency can present
similarly as a hemolytic anemia [1, 4–12] with similar
biochemical proles, thus leading to the initiation of plas-
mapheresis. is case is important in recognizing this rather
unusual presentation of severe vitamin B12 deciency.
Health providers should always act urgently if TTP is sus-
pected, but as this case points out, it is also important to keep
other rare causes of hemolytic anemia, such as severe vi-
tamin B12 deciency.
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